US 11,708,407 B2
Antigen binding molecule formats
Tong Zhang, New Rochelle, NY (US); Erica Pyles, New City, NY (US); Michael Rosconi, New City, NY (US); Nina Liu, Chappaqua, NY (US); Supriya Patel, Elmsford, NY (US); Eric Smith, New York, NY (US); Andrew Murphy, Croton-on-Hudson, NY (US); Chia-Yang Lin, Scarsdale, NY (US); and Samuel Davis, New York, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Feb. 7, 2022, as Appl. No. 17/666,116.
Application 17/666,116 is a continuation of application No. 16/987,487, filed on Aug. 7, 2020.
Claims priority of provisional application 63/050,483, filed on Jul. 10, 2020.
Claims priority of provisional application 62/884,496, filed on Aug. 8, 2019.
Prior Publication US 2022/0195030 A1, Jun. 23, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); A61K 39/395 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/395 (2013.01); A61K 47/6845 (2017.08); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 26 Claims
 
1. A pharmaceutical composition comprising an excipient and an antigen-binding molecule, the antigen-binding molecule comprising:
(a) a first polypeptide comprising, in an N- to C-terminal orientation:
(i) a first Fc domain; and
(ii) a first linker;
(iii) a first VH domain; and
(iv) a first CH1 domain,
wherein the first polypeptide lacks a binding domain N-terminal to the first Fc domain;
(b) a second polypeptide comprising, in an N- to C-terminal orientation:
(i) a second Fc domain;
(ii) a second linker;
(iii) a second VH domain; and
(iv) a second CH1 domain,
wherein the second polypeptide lacks a binding domain N-terminal to the second Fc domain;
(c) a third polypeptide associated with the first polypeptide comprising, in an N-to-C terminal orientation, a first VL domain and a first CL domain, wherein the first VL domain and the first CL domain are associated with the first VH domain and the first CH1 domain to form a first Fab domain; and
(d) a fourth polypeptide associated with the second polypeptide comprising, in an N-to-C terminal orientation, a second VL domain and a second CL domain, wherein the second VL domain and the second CL domain are associated with the second VH domain and the second CH1 domain to form a second Fab domain.